B
2.11
-0.02 (-0.94%)
| Previous Close | 2.13 |
| Open | 2.24 |
| Volume | 66,833 |
| Avg. Volume (3M) | 643,850 |
| Market Cap | 76,463,656 |
| Price / Book | 1.33 |
| 52 Weeks Range | |
| Earnings Date | 2 May 2025 - 16 May 2025 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 12.59% |
| Current Ratio (MRQ) | 3.39 |
| Operating Cash Flow (TTM) | -112.73 M |
| Levered Free Cash Flow (TTM) | -65.44 M |
| Return on Assets (TTM) | -56.38% |
| Return on Equity (TTM) | -104.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Biomea Fusion, Inc. | Bearish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 25.02% |
| % Held by Institutions | 63.55% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 1,795.74%) | Buy |
| Median | 16.00 (658.29%) | |
| Low | 3.00 (Barclays, 42.18%) | Hold |
| Average | 19.67 (832.23%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 2.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 02 Apr 2025 | 3.00 (42.18%) | Hold | 2.11 |
| HC Wainwright & Co. | 01 Apr 2025 | 40.00 (1,795.73%) | Buy | 2.11 |
| 31 Mar 2025 | 40.00 (1,795.73%) | Buy | 2.13 | |
| D. Boral Capital | 24 Mar 2025 | 16.00 (658.29%) | Buy | 2.79 |
| 19 Mar 2025 | 16.00 (658.29%) | Buy | 2.73 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |